Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Fan Zou,Lijuan Lu,Jun Liu,Baijin Xia,Wanying Zhang,Qifei Hu,Weiwei Liu,Yiwen Zhang,Yingtong Lin,Shuliang Jing,Mei Huang,Bifen Huang,Bingfeng Liu,Hui Zhang

DOI: https://doi.org/10.1038/s41467-019-11893-4

IF: 16.6

2019-01-01

Nature Communications

Abstract:The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpoint receptors simultaneously on CAR-T cells and that show the resulting PTL-CAR-T cells undergo epigenetic modifications and better control tumor growth. Furthermore, we unexpectedly find increased tumor infiltration by PTL-CAR-T cells and their clustering between the living and necrotic tumor tissue. Mechanistically, PTL-CAR-T cells upregulate CD56 (NCAM), which is essential for their effector function. The homophilic interaction between intercellular CD56 molecules correlates with enhanced infiltration of CAR-T cells, increased secretion of interferon-γ, and the prolonged survival of CAR-T cells. Ectopically expressed CD56 promotes CAR-T cell survival and antitumor response. Our findings demonstrate that genetic blockade of three checkpoint inhibitory receptors and the resulting high expression of CD56 on CAR-T cells enhances the inhibition of tumor growth.